Overview

Description

  • NatureRecombinant
  • SourceBaculovirus infected Sf9 cells
  • Amino Acid Sequence
    • SpeciesHuman

Specifications

Our Abpromise guarantee covers the use of ab60013 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Biological activitySpecific activity of 224 nmol/min/mg.
  • Applications

    Functional Studies

    SDS-PAGE

  • FormLiquid
  • Additional notes

    ab43624 (Human ERK2 full length protein) and ab43614 (Human Myelin Basic Protein full length protein) can be utilized as a substrate for assessing kinase activity

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped on dry ice. Upon delivery aliquot and store at -80ºC. Avoid freeze / thaw cycles.

    Preservative: None
    Constituents: 25% Glycerol, 50mM Tris HCl, 150mM Sodium chloride, 0.25mM DTT, 0.1mM EGTA, 0.1mM EDTA, 0.1mM PMSF, pH 7.5

    This product is an active protein and may elicit a biological response in vivo, handle with caution.

General Info

  • Alternative names
    • Cardiofaciocutaneous syndrome
    • CFC syndrome
    • CFC4
    • Dual specificity mitogen activated protein kinase kinase 2
    • Dual specificity mitogen-activated protein kinase kinase 2
    • ERK activator kinase 2
    • FLJ26075
    • MAP kinase kinase 2
    • map2k2
    • MAPK / ERK kinase 2
    • MAPK/ERK kinase 2
    • MAPKK 2
    • MAPKK2
    • MEK 2
    • MEK2
    • Microtubule associated protein kinase kinase 2
    • Mitogen activated protein kinase kinase 2
    • Mitogen activated protein kinase kinase 2 p45
    • MKK 2
    • MKK2
    • MP2K2_HUMAN
    • OTTHUMP00000165826
    • OTTHUMP00000165827
    • PRKMK 2
    • PRKMK2
    see all
  • FunctionCatalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases.
  • Involvement in diseaseDefects in MAP2K2 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
  • Sequence similaritiesBelongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications
    MAPKK is itself dependent on Ser/Thr phosphorylation for activity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).
    Acetylation of Ser-222 and Ser-226 by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
  • Information by UniProt

Recombinant human MEK2 protein images

  • Sample Kinase Activity Plot.
  • ab60013 on SDS-PAGE.

References for Recombinant human MEK2 protein (ab60013)

ab60013 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab60013.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"